ALDERLEY EDGE, UK--Zeneca Pharmaceuticals here has credited bioinformatics with a significant role in the company's recent success. Investments in bioinformatics, gene discovery, and human genetics have helped the firm convert raw genomic data into drug targets quickly, resulting in a current slate of 87 development projects, including 26 for new compounds, and plans to increase the company's research output. The comments came from company officials, including CEO Tom McKillop and Richard Auty, research and development director, in a meeting last week with analysts and investors.
They also noted that Zeneca has been enhancing its genomics capabilities through collaborations with such organizations as Incyte Pharmaceuticals, Molecular Dynamics, and Oxford University. The company's research output is set to double over the next five years, Zeneca claimed.